Rocket


Overview
Financials
News + Filings

 
 

Lyell Immunopharma, Inc. Add to portfolio


Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-20Dec-31-19
Revenues7.80.7
            Revenue growth1080.5% 
Cost of goods sold163.463.6
Gross profit-155.6-62.9
            Gross margin-2006.5%-9579.6%
General and administrative46.939.2
EBIT-211.9-102.1
            EBIT margin-2732.6%-15538.7%
Pre-tax income-204.5-129.4
Income taxes0.00.0
            Tax rate0.0%0.0%
Net income-204.5-129.4
            Net margin-2636.3%-19692.1%
 
Diluted EPS($204,472.00)($129,377.00)
Shares outstanding (diluted)0.00.0
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy